Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Wave Life Sciences Ltd.NASDAQ: WVE

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $22.1M rose 20.4% year over year, behind the +23.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Selling, general & admin amounted to 176.3% of revenue in FY2025, up 121.8 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 15 analysts of $225.62M (+199.5%) for the fiscal year ending Dec 2026, a step up from the +27.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$22.1M+5.8% QoQ
Last fiscal yearDec 2025
$75.33M+27.6% YoY
LTMMar 2026
$79.08M+23.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.4%+46.8%+26.4 pp
1 year+27.6%+199.5%+171.9 pp
3-year CAGR+14.3%+35.5%+21.3 pp
5-year CAGR+76.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
75.33M USD
Year-over-year change
+27.6%
4-year CAGR
+13.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.9% is the 5th highest of 10, against a peer median of +22.1%.
  • Selling, general & admin amounts to 110.1% of revenue for WVE, versus a peer median of 96.1%.
WVE Competitors
Selling, General & Admin for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.32B USD+22.1%+16.3%27.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M USD+66.3%+37.9%61.0%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$467.04M USD-17.3%+2.0%21.4%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$201.04M USD+64.9%+30.5%44.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$157.94M USD+14.5%+9.9%239.0%
WVEWave Life Sciences Ltd.LTM Mar 2026$79.08M USD+23.9%+14.3%110.1%
STOKStoke Therapeutics, Inc.LTM Mar 2026$71.21M USD+35.2%+19.9%222.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M USD-11.6%+0.0%96.1%
BNTCBenitec Biopharma Inc.LTM Mar 2026$34.74M USD+87.8%+52.2%—
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
Peer median (excluding WVE) —+22.1%+13.1%96.1%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.